The protein chip yields large amounts of data, being primarily aimed for use in biomedical research in academia, clinic and industry.

[1][3][4][5][6] In 2006 the basic technology of the position-encoded bead-based Arrays multiplex protein chip began to be developed in the research labs of the Department of Bioengineering, at the National University of Singapore (NUS).

[16][17][18][19][20] [21] In 2022 Ayoxxa closed a new financing round led by Hong Kong-based Prosnav Capital, with the stated goal of bringing funding to support operations and commercialization for 3-5 years.

[25][26] The multiplex technology approaches a level of analytical power (in throughput and accuracy) only previously seen in DNA sequencing arrays.

The technology is developed to run manually as well as fully automated, and giving more results quickly at high-throughput (yielding large amounts of data).

Ayoxxa's biochip can be used to identify thousands of different proteins in a single sample, including markers for diseases, where before numerous of the classic ELISA assays would be required to achieve the same results.

[3][7][10] To observe the reaction of the different antibodies to the sample, the chip is placed under a standard laboratory fluorescent microscope with a digital camera, which snaps shots of it.

[1][23] The technology centers on the patented In-situ Encoded Bead-based Arrays (IEBA),[29][30] originally developed at the National University of Singapore (NUS), of which Ayoxxa was made the exclusive licensee.

The coordinates of each individual bead in each sequential batch is recorded in a large map/decoding data table that is provided to the user alongside the carrier (like a USB flashdrive).

[23][26] This approach significantly reduces the complexity of downstream analysis while increasing the number of individual protein targets that can be analyzed in very low sample volumes.